AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
← catalyst calendarNCT06174805 · readout ≤ 377 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Suspended
Study type
Interventional
Design
Na · None · Treatment
Enrollment
67estimated
Sites
10
Countries
Belgium, Brazil, Canada +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-11 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Gastric Outlet Obstruction
Intervention
- Device: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Primary outcomes
what the primary-completion date above is the date OFSerious Adverse Events
measured Through study completion, an average of 1 year
Technical Success
measured During the procedure
Primary Effectiveness Endpoint
measured through 14 days after procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed